Science · 2018

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Show affiliations
  • Routy BGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Le Chatelier EMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
  • Derosa LGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Duong CPMGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Alou MTGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Daillère RGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Fluckiger AGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Messaoudene MGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Rauber CGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Roberti MPGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Fidelle MGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Flament CGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Poirier-Colame VGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Opolon PGustave Roussy, Laboratoire de Pathologie Expérimentale, 94800 Villejuif, France.
  • Klein CCentre de Recherche des Cordeliers, INSERM, Université Paris Descartes, Sorbonne Paris Cité, UMRS 1138, Université Pierre et Marie Curie Université Paris 06, Sorbonne Universités, Paris, France.
  • Iribarren KMetabolomics and Cell Biology Platforms, GRCC, Villejuif, France.
  • Mondragón LMetabolomics and Cell Biology Platforms, GRCC, Villejuif, France.
  • Jacquelot NGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Qu BGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Ferrere GGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Clémenson CGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Mezquita LGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Masip JRGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Naltet CThoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, France.
  • Brosseau SThoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, France.
  • Kaderbhai CDepartment of Medical Oncology, Center GF Leclerc, Dijon, France.
  • Richard CDepartment of Medical Oncology, Center GF Leclerc, Dijon, France.
  • Rizvi HDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Levenez FMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
  • Galleron NMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
  • Quinquis BMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
  • Pons NMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
  • Ryffel BMolecular Immunology and Embryology, UMR 7355, CNRS, University of Orleans, Orléans, France.
  • Minard-Colin VGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Gonin PGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Soria JCGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Deutsch EGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Loriot YGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Ghiringhelli FDepartment of Medical Oncology, Center GF Leclerc, Dijon, France.
  • Zalcman GThoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, France.
  • Goldwasser FParis Descartes University, Sorbonne Paris Cité, Paris, France.
  • Escudier BGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Hellmann MDDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Eggermont AGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Raoult DURMITE, Aix Marseille Université, UM63, CNRS 7278, IRD 198, INSERM 1095, IHU-Méditerranée Infection, 13005 Marseille, France.
  • Albiges LGustave Roussy Cancer Campus (GRCC), Villejuif, France.
  • Kroemer GMetabolomics and Cell Biology Platforms, GRCC, Villejuif, France. laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.
  • Zitvogel LGustave Roussy Cancer Campus (GRCC), Villejuif, France. laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.
29 read3 want to readRigor 3.0Novelty 3.4Impact 3.0Reprod. 2.4

Most-cited papers citing this

  • Nat Med · 2026 · cited by 3
  • Nature · 2026 · cited by 3
  • Cell Res · 2026 · cited by 2
  • Cytokine Growth Factor Rev · 2026 · cited by 2
  • Ann Surg Oncol · 2026 · cited by 2

Log in to like, log, and share thoughts on this paper.

Discussion

Share your thoughts above to start a thread. Constructive feedback only — reply to and like others’ posts.

0

Tom Nguyen

Rigor 5/5Novelty 4/5Impact 4/5Reprod. 5/5

Nice but incremental.

0

Noor Cohen

Rigor 3/5Novelty 5/5Impact 1/5Reprod. 1/5

Nice but incremental.

0

Alex Nguyen

Rigor 5/5Novelty 1/5Impact 2/5Reprod. 2/5

Important contribution to the field.

0

Nadia Sato

Rigor 3/5Novelty 1/5Impact 1/5Reprod. 4/5

Interesting idea, small sample.

0

Ines Mueller

Rigor 3/5Novelty 3/5Impact 3/5Reprod. 2/5

Solid methods, convincing results.

0

Ken Khan

Rigor 3/5Novelty 4/5Impact 5/5Reprod. 4/5

Nice but incremental.

0

Hugo Rossi

Rigor 5/5Novelty 2/5Impact 4/5Reprod. 2/5

Nice but incremental.

0

Noor Rossi

Rigor 3/5Novelty 5/5Impact 1/5Reprod. 1/5

Solid methods, convincing results.

0

Noor Kim

Rigor 1/5Novelty 3/5Impact 3/5Reprod. 3/5

Solid methods, convincing results.

0

Alex Mueller

Rigor 2/5Novelty 5/5Impact 5/5Reprod. 1/5

Nice but incremental.